Teva’s Allergan Generics Buy Progressing, Though Timeline Might Slip
This article was originally published in The Pink Sheet Daily
Executive Summary
The companies have been hoping to close the $40.5bn deal by the end of the first quarter, but the timeline could slip into April given the size of the portfolio and pipelines under regulatory review.
You may also be interested in...
Teva’s Rosy View For A Happy Union With Allergan Generics
The company provided updated mid-term guidance for the combined company, net revenues of $26.7bn to $27.8bn and EBITDA of $10.7bn to $11.5bn in 2019. The deal is expected to close any day, management assured investors.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.
CinFina Pushes Early Work In Obesity In Hopes Of A Deal
Emerging Company Profile: CinFina is advancing two novel mechanisms of action in obesity as monotherapies and in combination with GLP-1s.